Additionally, the Archer CSR Total Shoulder System, Catalyst’s stemless, ellipsoid anatomic system, has continued rapid adoption and growth. Today, the Archer shoulder systems have been used in more than 3,000 surgeries. The first patients are more than five years post-surgery with excellent clinical results.
“This funding round comes at a pivotal time for the Catalyst OrthoScience team,” said Brian K. Hutchison, chairman and CEO of Catalyst. “We are experiencing a significant period of growth, and this funding allows us to enhance our innovative product portfolio with further technological advancements in the shoulder arthroplasty space and expand our team across all areas.”
Catalyst OrthoScience raised $12.3 million in an oversubscribed Series D financing round.
Thus far in 2021, Catalyst has:
Rebranded its product portfolio with the Archer family name, Received FDA 510(k) clearance and began a limited launch for the Archer R1 Reverse Shoulder System and Introduced its Archer 3D Targeting...
Catalyst OrthoScience raised $12.3 million in an oversubscribed Series D financing round.
Thus far in 2021, Catalyst has:
Rebranded its product portfolio with the Archer family name,
Received FDA 510(k) clearance and began a limited launch for the Archer R1 Reverse Shoulder System and
Additionally, the Archer CSR Total Shoulder System, Catalyst’s stemless, ellipsoid anatomic system, has continued rapid adoption and growth. Today, the Archer shoulder systems have been used in more than 3,000 surgeries. The first patients are more than five years post-surgery with excellent clinical results.
“This funding round comes at a pivotal time for the Catalyst OrthoScience team,” said Brian K. Hutchison, chairman and CEO of Catalyst. “We are experiencing a significant period of growth, and this funding allows us to enhance our innovative product portfolio with further technological advancements in the shoulder arthroplasty space and expand our team across all areas.”
Copy to clipboard 
